A novel dermal tissue construct: development and in vitro characterization.
A dermal tissue construct composed of human dermal fibroblasts and a chitosan sponge has been developed, targeted towards the treatment of diabetic nonhealing ulcers. The construct has been designed in a way that the dermal fibroblasts are arranged as a three-dimensional sheet adhered entirely on one side of the chitosan sponge. This design would allow maximal diffusion of growth factors from the cells to the wound bed when the construct is applied on the wound with the cellular sheet side making contact with the wound bed. The diffusion of secreted growth factors would take place directly from cells to the wound bed without being impeded by a matrix. The cells are present at a high density in the dermal construct, which would aid in accelerated wound healing. The construct has a porous chitosan sponge base, which would allow gas exchange, and renders the dermal construct very flexible so that it would take the shape of the wound contours well, while having mechanical integrity. The viability of cells in the construct is greater than 90%. The dermal construct produces a high amount of vascular endothelial growth factor, from 42 ng to 31 ng in 24 h. The construct also produces high amounts of Interleukin-8 (IL-8), from 375 ng to 1065 ng in the first 24 h. Both VEGF and IL-8 have important roles in the healing of chronic diabetic ulcers.
Deshpande
Manisha S
MS
Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai, Maharashtra 400701, India. manisha_deshpande@relbio.com
Kuchroo
Pushpa V
PV
D002470:Cell Survival / Q000502:physiology; D002478:Cells, Cultured; D048271:Chitosan / Q000737:chemistry; D017719:Diabetic Foot / Q000628:therapy; D005347:Fibroblasts / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D012867:Skin / Q000166:cytology* / Q000378:metabolism / Q000473:pathology; D012883:Skin Ulcer / Q000628:therapy*; D023822:Tissue Engineering / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014945:Wound Healing / Q000502:physiology
D016209:Interleukin-8; D042461:Vascular Endothelial Growth Factor A; D048271:Chitosan